EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: Challenges and opportunities

Bárbara Silva, José Bragança

World Journal of Stem Cells · 26.02.2025 · 17 (2)

DOI: 10.4252/wjsc.v17.i2.99331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Stem Cells, online erschienen am 26.02.2025. Verfasst von Bárbara Silva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Algarve Biomedical Center-Research Institute, University of Algarve, Faro 8005-139, Portugal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The potential of induced pluripotent stem cells (iPSCs) for modeling and treating metabolic associated fatty liver disease (MAFLD) and metabolic associated steatohepatitis (MASH) is emerging. MAFLD is a growing global health concern, currently with limited treatment options. While primary mesenchymal stem cells hold promise, iPSCs offer a versatile alternative due to their ability to differentiate into various cell types, including iPSC-derived mesenchymal stem cells. However, challenges remain, including optimizing differentiation protocols, ensuring cell safety, and addressing potential tumorigenicity risks. In addition, iPSCs offer the possibility to generate complex cellular models, including three-dimensional organoid models, which are closer representations of the human disease than animal models. Those models would also be valuable for drug discovery and personalized medicine approaches. Overall, iPSCs and their derivatives offer new perspectives for advancing MAFLD/MASH research and developing novel therapeutic strategies. Further research is needed to overcome current limitations and translate this potential into effective clinical applications.

Schlagwörter

Stichwörter der Autor:innen

In vitro liver modelsInduced pluripotent stem cellsMesenchymal stem cellsMetabolic associated fatty liver diseaseMetabolic associated steatohepatitisNonalcoholic fatty liver diseaseNonalcoholic steatohepatitis

Autor:innen und Institutionen

  • Algarve Biomedical Center-Research Institute, University of Algarve, Faro 8005-139, Portugal.
  • Algarve Biomedical Center, University of Algarve, Faro 8005-139, Portugal.
  • Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro 8005-139, Portugal.
  • PhD Program in Biomedical Sciences, Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro 8005-139, Portugal.
  • Faculty of Medicine and Biomedical Sciences, Algarve Biomedical Center-Research Institute, University of Algarve, Faro 8005-139, Portugal.
  • Champalimaud Research Program, Champalimaud Centre for the Unknown, Lisbon 1000-001, Portugal. jebraganca@ualg.pt.

Zitieren

APA

Silva, B., & Bragança, J. (2025). Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: Challenges and opportunities. World Journal of Stem Cells, 17(2). https://doi.org/10.4252/wjsc.v17.i2.99331

Vancouver

Silva B, Bragança J. Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: Challenges and opportunities. World Journal of Stem Cells. 2025;17(2). doi:10.4252/wjsc.v17.i2.99331

BibTeX
@article{Silva2025,
  author = {Silva, Bárbara and Bragança, José},
  title = {Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: Challenges and opportunities},
  journal = {World Journal of Stem Cells},
  year = {2025},
  volume = {17},
  number = {2},
  doi = {10.4252/wjsc.v17.i2.99331}
}
Kostenlos starten →